The Senior Leadership is the central decision-making and internal advisory body, with the goal to encourage research productivity, promote interaction and collaboration, and take maximum advantage of institutional strengths and unique scientific opportunities. As Director, Dr. Donald Trump has broad authority over all aspects of the Cancer Center, and he is the ultimate visionary and decision-maker for scientific and administrative matters. The Deputy Director and Associate Directors are accomplished, productive scientists, having served on study sections, as well as important national advisory boards. The Senior Leaders are: Dr. Donald Trump, Director (recruited in 2002, appointed Director in 2007);Dr. Candace Johnson, Deputy Director (recruited in 2002, appointed in 2008);Dr. Alex Adjei, Associate Director for Clinical Research (2006);Dr. Andrei Gudkov, Associate Director for Basic Research (2007);Dr. Richard Hershberger, Chief Academic Officer (2011);Dr. James Marshall, Associate Director of Population Sciences Research (2002);Dr. James Mohler, Associate Director for Translational Research (recruited 2003, appointed 2008);and Brian Springer, Associate Director for Administration (2011). Each of the Senior Leaders also plays a pivotal role in CCSG Programs, Shared Resources, and/or administrative services. This team works closely and collaboratively to integrate RPCI research efforts, promote transdisciplinary interaction and collaboration, and set strategic direction and priorities. The leaders place specific emphasis on moving basic science research through the translational pipeline using internal and external mechanisms, as well as research focused within the RPCI catchment area. The leadership team builds and develops training and education programs to prepare future generations of cancer scientists. Over this funding cycle (2008 to 2013) and in accordance with the strategic plan, the Senior Leadership team worked together to recruit more than 137 cancer investigators and clinicians, of whom 51 are CCSG members. The group's emphasis on developing outstanding basic, translational, clinical, population science led to a 17% increase in peer-reviewed funding from $60.5 to $70.8 million. Efforts for development of investigator-initiated trials, resulted in an increase in institutional intervention accrual from 546 (2008) to 620 (2012), with institutional accrual rising from 60.3% to 71.3% of overall interventional accrual.
RPCI Senior Leadership works effectively to manage the Cancer Center Support Grant, establish the overall direction and plan strategically for the Institute. The leaders are responsible for clinical, basic and translational research efforts across all programmatic areas seeking to understand, prevent and cure cancer.
|Clyde, Merlise A; Palmieri Weber, Rachel; Iversen, Edwin S et al. (2016) Risk Prediction for Epithelial Ovarian Cancer in 11 United States-Based Case-Control Studies: Incorporation of Epidemiologic Risk Factors and 17 Confirmed Genetic Loci. Am J Epidemiol 184:579-589|
|Wilton, John; Kurenova, Elena; Pitzonka, Laura et al. (2016) Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs. Eur J Drug Metab Pharmacokinet 41:55-67|
|Zhao, Zhiguo; Wen, Wanqing; Michailidou, Kyriaki et al. (2016) Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. Cancer Causes Control 27:679-93|
|Goossens, Maria E; Isa, Fatima; Brinkman, Maree et al. (2016) International pooled study on diet and bladder cancer: the bladder cancer, epidemiology and nutritional determinants (BLEND) study: design and baseline characteristics. Arch Public Health 74:30|
|Pharoah, Paul D P; Song, Honglin; Dicks, Ed et al. (2016) PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations. J Natl Cancer Inst 108:|
|Austin, David C; Strand, Douglas W; Love, Harold L et al. (2016) NF-ÎºB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance. Prostate 76:1004-18|
|Sexton, Sandra; Tulowitzki, Ryan; Jones, Craig A et al. (2016) Involvement of the renin-angiotensin system in the development of nephrogenic systemic fibrosis-like lesions in the RenTag mouse model. Clin Exp Nephrol 20:162-8|
|Shafirstein, Gal; Battoo, Athar; Harris, Kassem et al. (2016) Photodynamic Therapy of Non-Small Cell Lung Cancer. Narrative Review and Future Directions. Ann Am Thorac Soc 13:265-75|
|Bistulfi, Gaia; Affronti, Hayley C; Foster, Barbara A et al. (2016) The essential role of methylthioadenosine phosphorylase in prostate cancer. Oncotarget 7:14380-93|
|Rohrbach, Daniel J; Rigual, Nestor; Arshad, Hassan et al. (2016) Intraoperative optical assessment of photodynamic therapy response of superficial oral squamous cell carcinoma. J Biomed Opt 21:18002|
Showing the most recent 10 out of 1099 publications